198 related articles for article (PubMed ID: 25087467)
1. Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy.
Yamamoto N; Minami S; Fujii M
Am J Otolaryngol; 2014; 35(6):731-5. PubMed ID: 25087467
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options.
Jaspers HC; Verbist BM; Schoffelen R; Mattijssen V; Slootweg PJ; van der Graaf WT; van Herpen CM
J Clin Oncol; 2011 Jun; 29(16):e473-6. PubMed ID: 21422415
[No Abstract] [Full Text] [Related]
3. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers.
Locati LD; Perrone F; Cortelazzi B; Lo Vullo S; Bossi P; Dagrada G; Quattrone P; Bergamini C; Potepan P; Civelli E; Fallai C; Pilotti S; Licitra L
Head Neck; 2016 May; 38(5):724-31. PubMed ID: 25522335
[TBL] [Abstract][Full Text] [Related]
4. Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy.
Soper MS; Iganej S; Thompson LD
Head Neck; 2014 Jan; 36(1):E4-7. PubMed ID: 23720164
[TBL] [Abstract][Full Text] [Related]
5. Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report.
Sheth H; Kumar P; Shreenivas A; Sambath J; Pragya R; Madre C; Athikari N; Khandare H; Peshattiwar V; Datar R; Limaye S
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036229
[No Abstract] [Full Text] [Related]
6. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma.
Fushimi C; Tada Y; Takahashi H; Nagao T; Ojiri H; Masubuchi T; Matsuki T; Miura K; Kawakita D; Hirai H; Hoshino E; Kamata S; Saotome T
Ann Oncol; 2018 Apr; 29(4):979-984. PubMed ID: 29211833
[TBL] [Abstract][Full Text] [Related]
7. Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.
Locati LD; Perrone F; Cortelazzi B; Imbimbo M; Bossi P; Potepan P; Civelli E; Rinaldi G; Quattrone P; Licitra L; Pilotti S
Cancer Biol Ther; 2014 Jun; 15(6):678-82. PubMed ID: 24618694
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.
Boon E; van Boxtel W; Buter J; Baatenburg de Jong RJ; van Es RJJ; Bel M; Fiets E; Oosting SF; Slingerland M; Hoeben A; Tesselaar MET; Jonker MA; Flucke UE; ; van der Graaf WTA; van Herpen CML
Head Neck; 2018 Mar; 40(3):605-613. PubMed ID: 29272069
[TBL] [Abstract][Full Text] [Related]
9. Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis.
Haderlein M; Scherl C; Semrau S; Lettmaier S; Hecht M; Erber R; Iro H; Fietkau R; Agaimy A
Strahlenther Onkol; 2017 Nov; 193(11):961-970. PubMed ID: 28828496
[TBL] [Abstract][Full Text] [Related]
10. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.
Boon E; Bel M; van Boxtel W; van der Graaf WTA; van Es RJJ; Eerenstein SEJ; Baatenburg de Jong RJ; van den Brekel MWM; van der Velden LA; Witjes MJH; Hoeben A; Willems SM; Bloemena E; Smit LA; Oosting SF; ; Jonker MA; Flucke UE; van Herpen CML
Int J Cancer; 2018 Aug; 143(4):758-766. PubMed ID: 29492965
[TBL] [Abstract][Full Text] [Related]
11. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.
Di Palma S; Simpson RH; Marchiò C; Skálová A; Ungari M; Sandison A; Whitaker S; Parry S; Reis-Filho JS
Histopathology; 2012 Oct; 61(4):629-43. PubMed ID: 22882517
[TBL] [Abstract][Full Text] [Related]
12. Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
van Boxtel W; Verhaegh GW; van Engen-van Grunsven IA; van Strijp D; Kroeze LI; Ligtenberg MJ; van Zon HB; Hendriksen Y; Keizer D; van de Stolpe A; Schalken JA; van Herpen CM
Int J Cancer; 2020 Jun; 146(11):3196-3206. PubMed ID: 31745978
[TBL] [Abstract][Full Text] [Related]
13. Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland.
Yamamoto H; Uryu H; Segawa Y; Tsuneyoshi M
Pathol Int; 2008 May; 58(5):322-6. PubMed ID: 18429833
[TBL] [Abstract][Full Text] [Related]
14. Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations.
Luk PP; Weston JD; Yu B; Selinger CI; Ekmejian R; Eviston TJ; Lum T; Gao K; Boyer M; O'Toole SA; Clark JR; Gupta R
Head Neck; 2016 Apr; 38 Suppl 1():E1838-47. PubMed ID: 26699379
[TBL] [Abstract][Full Text] [Related]
15. Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma.
Jeong ISD; Moyers J; Thung I; Thinn MM
Am J Case Rep; 2020 Jun; 21():e925181. PubMed ID: 32601266
[TBL] [Abstract][Full Text] [Related]
16. Combined androgen blockade for salivary gland carcinoma.
Gourd E
Lancet Oncol; 2018 Jan; 19(1):e17. PubMed ID: 29233558
[No Abstract] [Full Text] [Related]
17. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients.
Williams MD; Roberts D; Blumenschein GR; Temam S; Kies MS; Rosenthal DI; Weber RS; El-Naggar AK
Am J Surg Pathol; 2007 Nov; 31(11):1645-52. PubMed ID: 18059220
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target.
Yeoh CC; Dabab N; Rigby E; Chhikara R; Akaev I; Gomez RS; Fonseca F; Brennan PA; Rahimi S
J Oral Pathol Med; 2018 Aug; 47(7):691-695. PubMed ID: 29863801
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.
van Boxtel W; Locati LD; van Engen-van Grunsven ACH; Bergamini C; Jonker MA; Fiets E; Cavalieri S; Tooten S; Bos E; Quattrone P; Verhaegh GW; Schalken JA; Licitra L; van Herpen CML;
Eur J Cancer; 2019 Mar; 110():62-70. PubMed ID: 30771738
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.
Masubuchi T; Tada Y; Maruya S; Osamura Y; Kamata SE; Miura K; Fushimi C; Takahashi H; Kawakita D; Kishimoto S; Nagao T
Int J Clin Oncol; 2015 Feb; 20(1):35-44. PubMed ID: 24553861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]